Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen COVID-19 Vaccine Adds Another Thrombotic Warning

Executive Summary

US FDA adds a warning about immune thrombocytopenia, joining the risk of Thrombosis with Thrombocytopenia Syndrome.

You may also be interested in...



‘Most People Are Going To Get COVID’: US FDA’s Woodcock Not Ready To Shift To Endemic Policy

Acting FDA commissioner tell Senate committee that federal priority should be to ensure essential services remain functional as the Omicron variant’s spread continues.

CDC’s Walensky Suggests Higher Bar May Be Needed For Fourth COVID Vaccine Shots

Pfizer and Moderna have both indicated a fourth mRNA COVID vaccine may be needed. Companies may need to show waning protection against severe disease first.

With Many More COVID-19 Vaccine Changes Ahead, ACIP Expecting Fewer Public Meetings

CDC’s Advisory Committee on Immunization Practices wants a more feasible and sustainable meeting schedule in 2022, which would reduce transparency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel